University of Rochester, Department of Emergency Medicine
Welcome,         Profile    Billing    Logout  
 12 Trials 
13 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shah, Manish A
NCT03921021: Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Completed
2
17
US
Telomelysin, OBP-301
Weill Medical College of Cornell University, Oncolys BioPharma Inc
Esophagogastric Adenocarcinoma
06/23
07/23
NCT02998268: Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma

Active, not recruiting
2
42
US
Pembrolizumab, Keytruda, Taxol, Paclitaxel, Carboplatin
Weill Medical College of Cornell University, Merck Sharp & Dohme LLC
Esophageal Adenocarcinoma
02/21
09/26
CA209-76L, NCT04021108: Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol )

Active, not recruiting
2
80
US
Nivolumab 240 MG
Weill Medical College of Cornell University, Bristol-Myers Squibb
Gastroesophageal Adenocarcinoma
04/25
04/26
NCT06300463: Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

Recruiting
2
24
US
Botensilimab, AGEN1181, Balstilimab, AGEN2034, AGEN1423, Radiation
Weill Medical College of Cornell University, Agenus Inc.
Colorectal Cancer Metastatic, Liver Metastases, Colorectal Cancer
09/25
03/27
NCT06340711: Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Recruiting
2
27
US
OBP-301, Suratadenoturev, Pembrolizumab, Keytruda
Weill Medical College of Cornell University, Merck Sharp & Dohme LLC, Oncolys BioPharma Inc
Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
04/26
04/28
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
NCT05480384: Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Recruiting
2
25
US
Nivolumab, OPDIVO, Trastuzumab deruxtecan, ENHERTU
Brown University, AstraZeneca
Esophageal Adenocarcinoma, Esophageal Cancer, HER-2 Protein Overexpression, Gastroesophageal-junction Cancer
01/25
01/27
KEYNOTE-E58, NCT04041310: Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Active, not recruiting
1/2
115
Europe, Canada, US
GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®, pembrolizumab
Nouscom SRL, Merck Sharp & Dohme LLC
Solid Tumor, Adult
04/25
11/26
KISIMA-01, NCT04046445: Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

Active, not recruiting
1
96
Europe, US
ATP128, BI 754091, Ezabenlimab, VSV-GP128
Amal Therapeutics, Boehringer Ingelheim
Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer, Metastatic Colorectal Cancer, Liver Metastasis Colon Cancer
05/25
08/25
NCT04144699: Clinical Validation of Omron WheezeScan

Recruiting
N/A
240
US
Omron Healthcare Co., Ltd., University of Wisconsin, Madison, Children's Hospital Medical Center, Cincinnati, University of Chicago
Asthma in Children, Bronchitis, Bronchiolitis
11/21
12/21
NCT05809596: HEAL-LAA Clinical Trial

Active, not recruiting
N/A
949
US
WATCHMAN FLX Pro LAAC Device, Left Atrial Appendage Closure
Boston Scientific Corporation
Atrial Fibrillation, Bleeding, Stroke
07/24
08/25
CATALYST, NCT04226547: Amplatzer Amulet LAAO Vs. NOAC

Recruiting
N/A
2650
Europe, Canada, Japan, US, RoW
Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Amplatzer Amulet LAA Occluder, Non-Vitamin K Oral Antagonists, NOAC
Abbott Medical Devices
Atrial Fibrillation, Stroke, Bleeding
08/27
08/30
Adler, David
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30

Download Options